COLORADO SPRINGS, Colo.,
March 31, 2015 /PRNewswire/ --
Cannabis Science, Inc. (OTCQB: CBIS) today announced it has entered
into a one-year agreement with Derwin A.
Wallace to provide financial and investor relations services
for the Company. Mr. Wallace will focus on developing and expanding
the Company's financial communications with the institutional and
retail investment communities and initiate coverage from research
analysts through a comprehensive financial and investor relations
program.
"I am committed to putting all of my financial and operational
resources to work to help expedite company processes, and I am
looking forward to speaking with our shareholders about the
multiple drug development programs, product releases and patient
education systems strategies in motion," said Mr. Wallace.
"I expect my efforts should help speed up project results and
grow the operational cash flow in a faster time frame," he added.
"A number of key projects are underway, such as the Spain and California product releases, Netherlands pre-lab discussions, London, Italy
and Africa drug development
projects, Colorado and
Washington State formulation
releases, and Michigan State and NY
State initiatives. Projected potential revenues reflect these
projects. That, coupled with smart strategic moves the Company is
making, indicates the future of medical cannabis is here, and all
this doesn't even 'scratch the surface' of the real growth
potential of this Company."
Mr. Raymond C. Dabney, President
& CEO of Cannabis Science, Inc., said the new agreement
"reflects our commitment to our shareholders to create shareholder
value by setting into motion the $5M
– $25M and larger capital raises
required to take the Company and our suite of products to the next
level. With so much going on in the world of medical cannabis and
such rapid change, investors and analysts need to be able to make
rapid, educated decisions. Adding Mr. Wallace to the team is
our most significant, recent step in accomplishing just that, and
Mr. Wallace has the experience and expertise to help us tell our
story in a professional and transparent manner."
Prior to contracting with Cannabis Science, Mr. Wallace
accumulated more than 15 years of investor relations experience at
companies including Home Depot, Cox Cable, First Data, and ResCare.
As an investor relations professional, Mr. Wallace has extensive
experience communicating with and educating institutional
investors, retail investors and research analysts, including those
interested in the medical cannabis industry. In 2014, Mr. Wallace
decided to bring his investor relations experience to the cannabis
sector and assisted in creating the Cannabis Investor Conference
and founded the Cannabis Investor Webcast. Mr. Wallace holds an MBA
with a concentration in Finance from Keller
Graduate School of Management and a Bachelors of Science in
Accounting from DeVry University.
"The drug development and contemplated growth programs that are
underway strongly suggest a path of events and milestones of
immense proportions," said Mr. Wallace. "The multitude of projects
the Company has underway is spellbinding to say the least,
categorizing and creating a timeline is the only way to stay
adequately informed. It is astounding the amount of work this
Company has put in over the years to get to this point, and it
inspires me to join an organization with that level of
commitment."
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently,
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers,
HIV/AIDS, and neurological conditions. The Company is
proceeding with the research and development of its proprietary
drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1,
and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Mr. Derwin A. Wallace
Finance & Investor Relations
info@cannabisscience.com
Tel: 1.888.889.0888
Direct: 1.404.500.4950
Mr. Raymond C. Dabney
President & CEO, Co-Founder
info@cannabisscience.com
Tel: 1.888.889.0888
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cannabis-science-cbis-names-investor-relations-veteran-of-leading-companies-to-head-its-investor-relations-initiatives-300058385.html
SOURCE Cannabis Science, Inc.